Astellas Pharma Inc (ALPMY)
9.97
+0.27
(+2.78%)
USD |
OTCM |
May 02, 16:00
Astellas Pharma Price to Book Value: 1.677 for May 2, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 1.677 |
| May 01, 2024 | 1.632 |
| April 30, 2024 | 1.606 |
| April 29, 2024 | 1.620 |
| April 26, 2024 | 1.606 |
| April 25, 2024 | 1.605 |
| April 24, 2024 | 1.593 |
| April 23, 2024 | 1.596 |
| April 22, 2024 | 1.603 |
| April 19, 2024 | 1.598 |
| April 18, 2024 | 1.593 |
| April 17, 2024 | 1.591 |
| April 16, 2024 | 1.571 |
| April 15, 2024 | 1.560 |
| April 12, 2024 | 1.606 |
| April 11, 2024 | 1.731 |
| April 10, 2024 | 1.721 |
| April 09, 2024 | 1.761 |
| April 08, 2024 | 1.770 |
| April 05, 2024 | 1.783 |
| April 04, 2024 | 1.780 |
| April 03, 2024 | 1.798 |
| April 02, 2024 | 1.815 |
| April 01, 2024 | 1.812 |
| March 28, 2024 | 1.808 |
| Date | Value |
|---|---|
| March 27, 2024 | 1.840 |
| March 26, 2024 | 1.860 |
| March 25, 2024 | 1.833 |
| March 22, 2024 | 1.854 |
| March 21, 2024 | 1.862 |
| March 20, 2024 | 1.842 |
| March 19, 2024 | 1.830 |
| March 18, 2024 | 1.825 |
| March 15, 2024 | 1.821 |
| March 14, 2024 | 1.795 |
| March 13, 2024 | 1.798 |
| March 12, 2024 | 1.810 |
| March 11, 2024 | 1.832 |
| March 08, 2024 | 1.786 |
| March 07, 2024 | 1.808 |
| March 06, 2024 | 1.818 |
| March 05, 2024 | 1.817 |
| March 04, 2024 | 1.864 |
| March 01, 2024 | 1.876 |
| February 29, 2024 | 1.838 |
| February 28, 2024 | 1.847 |
| February 27, 2024 | 1.849 |
| February 26, 2024 | 1.855 |
| February 23, 2024 | 1.849 |
| February 22, 2024 | 1.844 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.560
Minimum
Apr 15 2024
2.868
Maximum
Jun 01 2020
2.331
Average
2.350
Median
Sep 13 2019
Price to Book Value Benchmarks
| Takeda Pharmaceutical Co Ltd | 0.871 |
| Nxera Pharma Co Ltd | 1.757 |
| PeptiDream Inc | 5.939 |
| Stemcell Holdings Inc | -- |
| Healios KK | 3.273 |
Price to Book Value Related Metrics
| PS Ratio | 1.640 |
| Price to Free Cash Flow | 18.92 |
| Price | 9.97 |
| Earnings Yield | -0.08% |
| Market Cap | 17.88B |
| Operating PE Ratio | 259.73 |